Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | XB628 |
| Synonyms | |
| Therapy Description |
XB628 is a bispecific antibody that targets PD-L1 on tumor cells and NKG2A on NK cells, potentially inducing tumor cell cytotoxicity (Cancer Res (2025) 85 (8_Supplement_1): 6067). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| XB628 | XB-628|XB 628 | NKG2A Antibody 4 PD-L1/PD-1 antibody 133 | XB628 is a bispecific antibody that targets PD-L1 on tumor cells and NKG2A on NK cells, potentially inducing tumor cell cytotoxicity (Cancer Res (2025) 85 (8_Supplement_1): 6067). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT06952010 | Phase I | XB628 | A Study of XB628 in Participants With Recurrent Advanced or Metastatic Solid Tumors | Recruiting | USA | 0 |